-
FDA Rejects Regulatory Filing For Zogenix Epilepsy Drug; GW Pharma Moves In Sympathy
Tuesday, April 9, 2019 - 9:05am | 439Zogenix, Inc. (NASDAQ: ZGNX), which develops therapies for rare diseases, said Monday afternoon the FDA issued a refusal to file letter regarding its NDA for Fintepla, chemically fenfluramine hydrochloride, which is being evaluated for the treatment of seizures associated with Dravet syndrome. The...
-
Zogenix Soars On Positive Phase 3 Data In Dravet Syndrome Study
Thursday, July 12, 2018 - 8:47am | 345Zogenix, Inc. (NASDAQ: ZGNX) peaked nearly 30 percent in Thursday's pre-market session after management released positive top-line results from its second pivotal Phase 3 study of ZX008 in Dravet Syndrome. The trial met primary and secondary endpoints and demonstrated statistical significance...